期刊文献+

抗帕金森性精神病药物哌马色林的合成

Synthesis of Pimavanserin for Parkinson’s Psychosis
下载PDF
导出
摘要 以对羟基苯乙酸为原料,经酯化、烷基化、酯水解、酰化、霍夫曼重排、水解和酰化反应合成了N-(4-异丁氧基苄基)氨基甲酸苯酯(9);再以对氟苄氨和N-甲基-4-哌啶酮为原料经过还原胺化生成4-(4-氟苄基氨基)-1-甲基哌啶(10);最后中间体(9)和中间体(10)经氨解反应合成哌马色林,总收率为50.2%,其结构经1H NMR和13C NMR确证。 Phenyl[4-(2-methylpropoxy)benzyl]carbamate(9)was synthesized by seven-steps reactions of esterification,alkylation,hydrolysis,acylation,Hofmann rearrangement,hydrolysis,and acylation using 4-hydroxyphenylacetic acid as the starting material;then 4-(4-fluorobenzylamino)-1-methylpiperidine(10)was obtained by Borch reduction using 4-fluorobenzylamine and N-methyl-4-piperidinone as the starting materials;finally the resulting product(9)underwent an ammonolysis reaction with 4-(4-fluorobenzylamino)-1-methyl piperidine(10)to give the final product of Pimavanserin with the total yield of 50.2%.The structure of Pimavanserin was confirmed by 1H NMR and 13C NMR.
作者 胡昆 张美菊 吴冬冬 谢宇轩 江书琦 任杰 HU Kun;ZHANG Mei-ju;WU Dong-dong;XIE Yu-xuan;JIANG Shu-qi;REN Jie(School of Pharmaceutical Engineering&Life Science,Changzhou University,Changzhou 213164,China)
出处 《合成化学》 CAS 北大核心 2020年第4期330-335,共6页 Chinese Journal of Synthetic Chemistry
基金 江苏省产学研合作“前瞻性联合研究项目”(BY2015027-13)。
关键词 对羟基苯乙酸 霍夫曼重排 哌马色林 合成 还原反应 氨解反应 4-hydroxyphenylacetic acid hofmann rearrangement pimavanserin synthesis
  • 相关文献

参考文献2

二级参考文献27

  • 1Zhang ZX, Ramsn GC, Hang Z, et al. Parkinson's disease in China: prevalence in Beijing, Xian and Shanghai [ J ]. Lancet, 2005, 365 : 595-597.
  • 2Gardian G, Vecsei L. Medical treatment of Parkinson's disease:today and the future[ J]. International Journal of Clinical Pharmacology and Therapeutics,2010,48:633-642.
  • 3Daniel W, Howard H, Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies [ J ]. Am J Psychiatry,2007,164 : 1491-1498.
  • 4Friedman JH, Fernandez HH. The non-motor problems of Parkinson disease[J]. Neurology,2000,6 : 18-27.
  • 5Chen JJ. Anxiety ,depression and psychosis in Parkinsen's disease: unmet needs and treatment challenges [ J ]. Neurol Clin, 2004,22 : S63-90.
  • 6Fabbrini G, Barbanti P, Aufilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease [J]. Neurol Sci ,2002,23:41-43.
  • 7Bergman J, Lemer V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease [ J ]. Clin Neuropharmacol,2002,25 : 107-110.
  • 8Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease [J]. J Geriatr Psychiatry Neurel,2003,16 : 184-188.
  • 9Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease : a randomised, double blind, placebo controlled, crossover study [J]. J Neurol Neurosurg Psychiatry, 2005,76 : 934- 939.
  • 10Aarsland D, Laake K, Larsen J, et al. Donepezil for cognitive impairment in parkinson's disease: a randomized controlled study [J]. J Neurol Neurosurg Psychiatry,2002 ,72 :708-712.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部